PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Abroad (travel likely)RecruitingPHASE1

Conditions

Neuroendocrine Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Contact: Study coordinator (MC Research Manager) · NMResearch@petermac.org · +61385596602

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Gastroenteropancreatico Tumors · Neuroendocrine Tumors · Neuroendocrine Neoplasms

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

Malignant Brain Neoplasm · Malignant Solid Neoplasm · Multiple Sclerosis

Abroad (travel likely)Recruiting

Rochester, United States

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Neuroendocrine Tumors · Progression · Neuroendocrine Tumor Grade 1

Abroad (travel likely)RecruitingPHASE2

São Paulo, Brazil · São Paulo, Brazil

Observational Study on GEP-and Pulm-NET Treated at FPG

Neuroendocrine Tumors · Gep Net · Pulmonary Neuroendocrine Neoplasm

Abroad (travel likely)Recruiting

Rome, Italy